What is Neurocrine Biosciences's total equity?

Neurocrine Biosciences (NBIX) reported total equity of $3.41B in Q1 2026.

How has Neurocrine Biosciences's total equity changed year-over-year?

Neurocrine Biosciences's total equity increased by 34.4% year-over-year, from $2.54B to $3.41B.

What is the long-term trend for Neurocrine Biosciences's total equity?

Over 5 years (2020 to 2025), Neurocrine Biosciences's total equity has grown at a 23.6% compound annual growth rate (CAGR), from $1.13B to $3.25B.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Neurocrine Biosciences NBIX Total Equity

Total Equity at other companies

Bristol-Myers SquibbBMY

$20.07B+15.4%

Acadia PharmaceuticalsACAD

$1.25B+63.1%

Crinetics PharmaceuticalsCRNX

$1.28B+2.1%

Solid Biosciences Inc.SLDB

$374.13M+27.1%

MapLight Therapeutics, Inc. MPLT

$399.83M+285%

BridgeBio PharmaBBIO

-$2.28B-38.2%

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$17.3B+30.9%

Enterprise value$17.49B+30.2%

P/E25.9×-12.1×

P/S5.6×+0.3×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's total equity?: Neurocrine Biosciences (NBIX) reported total equity of $3.41B in Q1 2026.
How has Neurocrine Biosciences's total equity changed year-over-year?: Neurocrine Biosciences's total equity increased by 34.4% year-over-year, from $2.54B to $3.41B.
What is the long-term trend for Neurocrine Biosciences's total equity?: Over 5 years (2020 to 2025), Neurocrine Biosciences's total equity has grown at a 23.6% compound annual growth rate (CAGR), from $1.13B to $3.25B.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.